Industry Research Reports

Home > Reports > Medical Care > Nonalcoholic Steatohepatitis (NASH) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Nonalcoholic Steatohepatitis (NASH) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 106 Pages

Report ld: 2342323

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.

The global market for Nonalcoholic Steatohepatitis (NASH) was estimated to be worth US$ 3064.2 million in 2023 and is forecast to a readjusted size of US$ 46230 million by 2030 with a CAGR of 46.7% during the forecast period 2024-2030

Nonalcoholic Steatohepatitis (NASH) Market Size

M= millions and B=billions

Non-alcoholic drinks, also known as mocktails or alcohol-free beverages, are beverages that do not contain any alcohol. These drinks are a popular choice for those who do not consume alcohol, including designated drivers, people who are underage, or individuals who wish to avoid alcohol for personal or health reasons. There are a wide variety of non-alcoholic drinks available, ranging from soft drinks to fresh juices, herbal infusions, and specialty mocktails. Some examples of non-alcoholic drinks include: 1. Soft Drinks: This category includes popular carbonated beverages like cola, lemon-lime sodas, ginger ale, and root beer. These drinks are often sweet and fizzy, providing a refreshing and enjoyable beverage option. 2. Fruit Juices: Freshly squeezed or packaged fruit juices, such as orange, apple, grapefruit, pineapple, or cranberry juice, are a common choice. These juices offer a natural and flavorful alternative to alcoholic beverages. 3. Smoothies: Made from a blend of fruits, vegetables, yogurt, and other ingredients, smoothies provide a nutritious and wholesome non-alcoholic option. They can be customized with various flavors and ingredients to suit individual preferences. 4. Herbal Infusions and Tea: Herbal teas and infusions, such as chamomile, peppermint, green tea, or hibiscus tea, are popular choices. These beverages are caffeine-free and often have relaxing or soothing properties. 5. Mocktails: These are non-alcoholic cocktails that mimic the flavors and presentation of traditional cocktails. They are typically made with a combination of juices, sodas, and garnishes, providing a fancy and enjoyable experience without the alcohol. 6. Sparkling Water: Carbonated water or mineral water with added flavors or fruit infusions is a refreshing and hydrating option. It is often consumed plain or mixed with juices or syrups. These non-alcoholic drinks offer a variety of flavors, textures, and options for those who prefer not to consume alcohol. They are a great way to enjoy a beverage while socializing or relaxing without the effects of alcohol.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Nonalcoholic Steatohepatitis (NASH), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Nonalcoholic Steatohepatitis (NASH) by region & country, by Type, and by Application.

The Nonalcoholic Steatohepatitis (NASH) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonalcoholic Steatohepatitis (NASH).

Market Segmentation

Report Metric
Details
Report Title
Nonalcoholic Steatohepatitis (NASH) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 46230 million
CAGR(2024-2030)
46.7%
Market Size Available for Years
2019-2030
Global Nonalcoholic Steatohepatitis (NASH) Companies Covered
AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead
Global Nonalcoholic Steatohepatitis (NASH) Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nonalcoholic Steatohepatitis (NASH) Market, Segment by Type
Obeticholic acid（OCA）

Selonsertib
Global Nonalcoholic Steatohepatitis (NASH) Market, Segment by Application
Hospital Pharmacy

Online Provider

Retail Pharmacy
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nonalcoholic Steatohepatitis (NASH) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Nonalcoholic Steatohepatitis (NASH) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Nonalcoholic Steatohepatitis (NASH) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Nonalcoholic Steatohepatitis (NASH) Product Introduction
    1.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast
    1.3 Nonalcoholic Steatohepatitis (NASH) Market Trends & Drivers
        1.3.1 Nonalcoholic Steatohepatitis (NASH) Industry Trends
        1.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers & Opportunity
        1.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
        1.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Nonalcoholic Steatohepatitis (NASH) Players Revenue Ranking (2023)
    2.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue by Company (2019-2024)
    2.3 Key Companies Nonalcoholic Steatohepatitis (NASH) Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Nonalcoholic Steatohepatitis (NASH) Product Offered
    2.5 Key Companies Time to Begin Mass Production of Nonalcoholic Steatohepatitis (NASH)
    2.6 Nonalcoholic Steatohepatitis (NASH) Market Competitive Analysis
        2.6.1 Nonalcoholic Steatohepatitis (NASH) Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Obeticholic acid（OCA）
        3.1.2 Selonsertib
    3.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Type
        3.2.1 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Value, by Type (2019-2030)
        3.2.3 Global Nonalcoholic Steatohepatitis (NASH) Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital Pharmacy
        4.1.2 Online Provider
        4.1.3 Retail Pharmacy
    4.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Application
        4.2.1 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Value, by Application (2019-2030)
        4.2.3 Global Nonalcoholic Steatohepatitis (NASH) Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region
        5.1.1 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region (2019-2024)
        5.1.3 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region (2025-2030)
        5.1.4 Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        5.2.2 North America Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        5.3.2 Europe Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        5.4.2 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        5.5.2 South America Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        5.6.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Nonalcoholic Steatohepatitis (NASH) Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Nonalcoholic Steatohepatitis (NASH) Sales Value
    6.3 United States
        6.3.1 United States Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        6.3.2 United States Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Nonalcoholic Steatohepatitis (NASH) Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        6.4.2 Europe Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Nonalcoholic Steatohepatitis (NASH) Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        6.5.2 China Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Nonalcoholic Steatohepatitis (NASH) Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        6.6.2 Japan Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Nonalcoholic Steatohepatitis (NASH) Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        6.7.2 South Korea Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Nonalcoholic Steatohepatitis (NASH) Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        6.8.2 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019-2030
        6.9.2 India Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Nonalcoholic Steatohepatitis (NASH) Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 AstraZeneca
        7.1.1 AstraZeneca Profile
        7.1.2 AstraZeneca Main Business
        7.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.1.4 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.1.5 AstraZeneca Recent Developments
    7.2 Arena Pharmaceuticals
        7.2.1 Arena Pharmaceuticals Profile
        7.2.2 Arena Pharmaceuticals Main Business
        7.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.2.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.2.5 Arena Pharmaceuticals Recent Developments
    7.3 GSK
        7.3.1 GSK Profile
        7.3.2 GSK Main Business
        7.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.3.4 GSK Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.3.5 Novo Nordisk Recent Developments
    7.4 Novo Nordisk
        7.4.1 Novo Nordisk Profile
        7.4.2 Novo Nordisk Main Business
        7.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.4.4 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.4.5 Novo Nordisk Recent Developments
    7.5 Roche
        7.5.1 Roche Profile
        7.5.2 Roche Main Business
        7.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.5.4 Roche Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.5.5 Roche Recent Developments
    7.6 Vivus
        7.6.1 Vivus Profile
        7.6.2 Vivus Main Business
        7.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.6.4 Vivus Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.6.5 Vivus Recent Developments
    7.7 Arisaph Pharmaceuticals
        7.7.1 Arisaph Pharmaceuticals Profile
        7.7.2 Arisaph Pharmaceuticals Main Business
        7.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.7.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.7.5 Arisaph Pharmaceuticals Recent Developments
    7.8 Cempra Pharmaceuticals
        7.8.1 Cempra Pharmaceuticals Profile
        7.8.2 Cempra Pharmaceuticals Main Business
        7.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.8.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.8.5 Cempra Pharmaceuticals Recent Developments
    7.9 Galectin Therapeutics
        7.9.1 Galectin Therapeutics Profile
        7.9.2 Galectin Therapeutics Main Business
        7.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.9.4 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.9.5 Galectin Therapeutics Recent Developments
    7.10 Galmed Pharmaceuticals
        7.10.1 Galmed Pharmaceuticals Profile
        7.10.2 Galmed Pharmaceuticals Main Business
        7.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.10.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.10.5 Galmed Pharmaceuticals Recent Developments
    7.11 Genfit
        7.11.1 Genfit Profile
        7.11.2 Genfit Main Business
        7.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.11.4 Genfit Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.11.5 Genfit Recent Developments
    7.12 Gilead
        7.12.1 Gilead Profile
        7.12.2 Gilead Main Business
        7.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
        7.12.4 Gilead Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) & (2019-2024)
        7.12.5 Gilead Recent Developments

 8 Industry Chain Analysis
    8.1 Nonalcoholic Steatohepatitis (NASH) Industrial Chain
    8.2 Nonalcoholic Steatohepatitis (NASH) Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Nonalcoholic Steatohepatitis (NASH) Sales Model
        8.5.2 Sales Channel
        8.5.3 Nonalcoholic Steatohepatitis (NASH) Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Nonalcoholic Steatohepatitis (NASH) Market Trends
    Table 2. Nonalcoholic Steatohepatitis (NASH) Market Drivers & Opportunity
    Table 3. Nonalcoholic Steatohepatitis (NASH) Market Challenges
    Table 4. Nonalcoholic Steatohepatitis (NASH) Market Restraints
    Table 5. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Nonalcoholic Steatohepatitis (NASH) Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Nonalcoholic Steatohepatitis (NASH) Product Type
    Table 9. Key Companies Time to Begin Mass Production of Nonalcoholic Steatohepatitis (NASH)
    Table 10. Global Nonalcoholic Steatohepatitis (NASH) Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region (2019-2024) & (%)
    Table 27. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Nonalcoholic Steatohepatitis (NASH) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Nonalcoholic Steatohepatitis (NASH) Sales Value, (2025-2030) & (US$ Million)
    Table 31. AstraZeneca Basic Information List
    Table 32. AstraZeneca Description and Business Overview
    Table 33. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of AstraZeneca (2019-2024)
    Table 35. AstraZeneca Recent Developments
    Table 36. Arena Pharmaceuticals Basic Information List
    Table 37. Arena Pharmaceuticals Description and Business Overview
    Table 38. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Arena Pharmaceuticals (2019-2024)
    Table 40. Arena Pharmaceuticals Recent Developments
    Table 41. GSK Basic Information List
    Table 42. GSK Description and Business Overview
    Table 43. GSK Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of GSK (2019-2024)
    Table 45. GSK Recent Developments
    Table 46. Novo Nordisk Basic Information List
    Table 47. Novo Nordisk Description and Business Overview
    Table 48. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Novo Nordisk (2019-2024)
    Table 50. Novo Nordisk Recent Developments
    Table 51. Roche Basic Information List
    Table 52. Roche Description and Business Overview
    Table 53. Roche Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Roche (2019-2024)
    Table 55. Roche Recent Developments
    Table 56. Vivus Basic Information List
    Table 57. Vivus Description and Business Overview
    Table 58. Vivus Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Vivus (2019-2024)
    Table 60. Vivus Recent Developments
    Table 61. Arisaph Pharmaceuticals Basic Information List
    Table 62. Arisaph Pharmaceuticals Description and Business Overview
    Table 63. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Arisaph Pharmaceuticals (2019-2024)
    Table 65. Arisaph Pharmaceuticals Recent Developments
    Table 66. Cempra Pharmaceuticals Basic Information List
    Table 67. Cempra Pharmaceuticals Description and Business Overview
    Table 68. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Cempra Pharmaceuticals (2019-2024)
    Table 70. Cempra Pharmaceuticals Recent Developments
    Table 71. Galectin Therapeutics Basic Information List
    Table 72. Galectin Therapeutics Description and Business Overview
    Table 73. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Galectin Therapeutics (2019-2024)
    Table 75. Galectin Therapeutics Recent Developments
    Table 76. Galmed Pharmaceuticals Basic Information List
    Table 77. Galmed Pharmaceuticals Description and Business Overview
    Table 78. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Galmed Pharmaceuticals (2019-2024)
    Table 80. Galmed Pharmaceuticals Recent Developments
    Table 81. Genfit Basic Information List
    Table 82. Genfit Description and Business Overview
    Table 83. Genfit Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Genfit (2019-2024)
    Table 85. Genfit Recent Developments
    Table 86. Gilead Basic Information List
    Table 87. Gilead Description and Business Overview
    Table 88. Gilead Nonalcoholic Steatohepatitis (NASH) Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Nonalcoholic Steatohepatitis (NASH) Business of Gilead (2019-2024)
    Table 90. Gilead Recent Developments
    Table 91. Key Raw Materials Lists
    Table 92. Raw Materials Key Suppliers Lists
    Table 93. Nonalcoholic Steatohepatitis (NASH) Downstream Customers
    Table 94. Nonalcoholic Steatohepatitis (NASH) Distributors List
    Table 95. Research Programs/Design for This Report
    Table 96. Key Data Information from Secondary Sources
    Table 97. Key Data Information from Primary Sources
    Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Nonalcoholic Steatohepatitis (NASH) Product Picture
    Figure 2. Global Nonalcoholic Steatohepatitis (NASH) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Nonalcoholic Steatohepatitis (NASH) Sales Value (2019-2030) & (US$ Million)
    Figure 4. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
    Figure 5. Global Nonalcoholic Steatohepatitis (NASH) Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2023
    Figure 7. Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Obeticholic acid（OCA） Picture
    Figure 9. Selonsertib Picture
    Figure 10. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Hospital Pharmacy
    Figure 13. Product Picture of Online Provider
    Figure 14. Product Picture of Retail Pharmacy
    Figure 15. Global Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Nonalcoholic Steatohepatitis (NASH) Sales Value Market Share by Application, 2023 & 2030
    Figure 17. North America Nonalcoholic Steatohepatitis (NASH) Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe Nonalcoholic Steatohepatitis (NASH) Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America Nonalcoholic Steatohepatitis (NASH) Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions Nonalcoholic Steatohepatitis (NASH) Sales Value (%), (2019-2030)
    Figure 28. United States Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (%), 2023 VS 2030
    Figure 31. Europe Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (%), 2023 VS 2030
    Figure 34. China Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
    Figure 36. China Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (%), 2023 VS 2030
    Figure 37. Japan Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (%), 2023 VS 2030
    Figure 40. South Korea Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (%), 2023 VS 2030
    Figure 43. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (%), 2023 VS 2030
    Figure 46. India Nonalcoholic Steatohepatitis (NASH) Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India Nonalcoholic Steatohepatitis (NASH) Sales Value by Type (%), 2023 VS 2030
    Figure 48. India Nonalcoholic Steatohepatitis (NASH) Sales Value by Application (%), 2023 VS 2030
    Figure 49. Nonalcoholic Steatohepatitis (NASH) Industrial Chain
    Figure 50. Nonalcoholic Steatohepatitis (NASH) Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.

The global market for Nonalcoholic Steatohepatitis (NASH) was estimated to be worth US$ 3064.2 million in 2023 and is forecast to a readjusted size of US$ 46230 million by 2030 with a CAGR of 46.7% during the forecast period 2024-2030

Market Segmentation

Industry: Medical Care

Published: 2024-01-24

Pages: 106 Pages

Report ld: 2342323

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 3950.00

Multi Users License

USD 5925.00